CMS denies coverage of FDA-approved treatments that target amyloid for Alzheimer's disease unless th...
Read moreThe Project Orbis initiative is an international partnership between medicines regulators in the UK,...
Read moreCollectively, companies still owe AIFA €370 million of the €2.8 billion that industry has to rep...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreAmong the most expensive therapies are gene therapies that show promise to transform inherited disor...
Read moreThe Federal Joint Committee (G-BA) has set out criteria for ATMPs which are likely to require qualit...
Read moreThe provision of funding for Early Access Programmes is not ubiquitous. We explore which EU5 countri...
Read moreOur experts provide an overview of the five key trends that could shape the pricing and market acces...
Read moreOur experts reflect on the trends that shaped the European pricing and market access landscape in 20...
Read moreWe summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...
Read more